Released May 13, 2022, during market hours
10-Q filed May 13, 2022, 43 days after period end · 0001564590-22-020039
Q1 2022 · 10-Q
Revenue$2.02M$2.02M +21.8% vs Q1 2021+9.6% vs Q4 2021
Net Income-$9.00K-$9.00K N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted$0.00$0.00 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income$25,000N/M
Operating Cash Flow-$23,000N/M
Margins · derived
Operating margin1.2%+35.4 pt vs Q1 2021
Net margin-0.4%+35.7 pt vs Q1 2021
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $2.02M | $1.66M | $2.36M | $2.22M |
| Net Income | -$9.00K | -$599.00K | -$373.00K | -$906.00K |
| EPS Diluted | $0.00 | -$0.08 | -$0.05 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
International Stem Cell CORP · CIK 1355790 · Engraved from SEC EDGAR